Steve Brocchini
Overview
Explore the profile of Steve Brocchini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
962
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ma Y, Yu Z, Waudby C, Ju T, Zhou X, Brocchini S, et al.
Int J Pharm
. 2024 Dec;
669():125039.
PMID: 39662858
Sunitinib malate (SUM), widely used in cancer treatment for its anti-VEGF properties, has also been explored for ocular neovascular diseases. For ocular applications, sustained drug release is essential to reduce...
2.
Schlosser C, Morris C, Brocchini S, Williams G
Int J Pharm
. 2024 Nov;
667(Pt B):124885.
PMID: 39491655
Electrospraying is a processing technique that has gained much interest to prepare polymeric particles. The technique operates at ambient temperature, thereby avoiding heat induced degradation of labile therapeutics (e.g. peptides...
3.
Schlosser C, Rozek W, Mellor R, Manka S, Morris C, Brocchini S, et al.
Int J Pharm
. 2024 Oct;
667(Pt A):124853.
PMID: 39437847
Teriparatide (and analogue peptides) are the only FDA approved anabolic treatments for osteoporosis. Current therapies are administered as a daily subcutaneous injection, which limits patient adherence and clinical efficacy. To...
4.
Pandya A, Zhang C, Barata T, Brocchini S, Howard M, Zloh M, et al.
Mol Pharm
. 2024 Oct;
21(11):5497-5509.
PMID: 39431440
The design of stable formulations remains a major challenge for protein therapeutics, particularly the need to minimize aggregation. Experimental formulation screens are typically based on thermal transition midpoints (), and...
5.
Collins M, Ibeanu N, Grabowska W, Awwad S, Khaw P, Brocchini S, et al.
RSC Chem Biol
. 2024 Sep;
PMID: 39347456
We previously described FpFs 1̲ (Fab-PEG-Fab) as binding mimetics of IgGs. FpFs are prepared with di(bis-sulfone) conjugation reagents 3̲ that undergo disulfide rebridging conjugation with the accessible disulfide of each...
6.
Al-Bassam L, Shearman G, Brocchini S, Alany R, Williams G
Pharmaceutics
. 2024 May;
16(5).
PMID: 38794293
Oxidative stress plays a critical role in the development of chronic ocular conditions including cataracts, age-related macular degeneration, and diabetic retinopathy. There is a need to explore the potential of...
7.
Bakhtiari S, Zhu Z, Magdysyuk O, Brocchini S, Williams G
Int J Pharm
. 2023 Aug;
644:123291.
PMID: 37544388
This study focuses on the use of methacrylic acid polymers synthesised via the Reversible Addition Fragmentation chain Transfer (RAFT) polymerisation method for the production of amorphous solid dispersions (ASDs) by...
8.
Ma Y, Brocchini S, Williams G
J Control Release
. 2023 Aug;
361:280-296.
PMID: 37536545
Extracellular vesicles (EVs) are small membrane-bound vesicles released by cells. EVs are emerging as a promising class of therapeutic entity that could be adapted in formulation due to their lack...
9.
Awwad S, Ibeanu N, Liu T, Velentza-Almpani A, Chouhan N, Vlatakis S, et al.
Pharmaceutics
. 2023 May;
15(5).
PMID: 37242686
Real-time measurement is important in modern dissolution testing to aid in parallel drug characterisation and quality control (QC). The development of a real-time monitoring platform (microfluidic system, a novel eye...
10.
Abedin Zadeh M, Alany R, Satarian L, Shavandi A, Abdullah Almousa M, Brocchini S, et al.
Pharmaceutics
. 2023 May;
15(5).
PMID: 37242572
There are limited treatments currently available for retinal diseases such as age-related macular degeneration (AMD). Cell-based therapy holds great promise in treating these degenerative diseases. Three-dimensional (3D) polymeric scaffolds have...